{"id":"anti-cd20-targeting-agent","rwe":[],"tags":[],"phase":"discontinued","safety":{"boxedWarnings":[],"safetySignals":[],"drugInteractions":[],"commonSideEffects":[],"contraindications":[],"specialPopulations":{},"discontinuationRates":[],"seriousAdverseEvents":[]},"status":"discontinued","trials":["NCT01307267","NCT02663518","NCT03530683","NCT05099471"],"aliases":[],"patents":[],"pricing":[],"allNames":"anti-cd20 targeting agent","offLabel":[],"timeline":[{"date":"2019","type":"neutral","milestone":"Phase 1 Initiated","description":"Phase 1 trial (A Study Of PF-05082566 As A Single Agent And In Combination With Rituximab) — Lymphoma, Non-Hodgkin"},{"date":"2028","type":"neutral","milestone":"Phase 2 Initiated","description":"Phase 2 trial (Efficacy of Venetoclax in Combination With Rituximab in Waldenström's Macroglobulinemia) — Waldenstrom Macroglobulinemia"}],"aiSummary":"Anti-CD20 Targeting agent is a monoclonal antibody that binds to CD20 protein found on B cells, leading to their destruction. It is approved for treating B-cell malignancies and certain autoimmune conditions where B cells play a pathogenic role. This mechanism allows for selective depletion of abnormal or overactive B cells while preserving other immune functions.","brandName":"Anti-CD20 Targeting agent","companyId":"pfizer","ecosystem":[],"mechanism":{"target":"","novelty":"","modality":"","drugClass":"Days 1,8,15, and 22 of the first 28-day cycle and then on Day 1 of subsequent 21-day cycles. The ant","explanation":"Anti-CD20 Targeting agent works by recognizing and binding to CD20, a protein marker found on the surface of B cells. B cells are white blood cells that play important roles in both normal immunity and in certain diseases. By targeting CD20, this drug can selectively identify and eliminate B cells that are causing disease.\n\nOnce the drug binds to CD20 on B cells, it triggers several mechanisms of cell destruction. The immune system recognizes these marked cells as targets and destroys them through various pathways. Additionally, the drug can cause B cells to undergo programmed cell death directly. This results in a significant reduction in the number of B cells circulating in the body and in affected tissues.\n\nThis selective B cell depletion is beneficial in conditions where B cells are either malignant (cancerous) or are mistakenly attacking the body's own tissues. By removing these problematic cells, the drug can shrink tumors, reduce cancer progression, or suppress harmful autoimmune responses. The effect is temporary, and B cells gradually repopulate over time, which is why patients typically require repeated treatments to maintain clinical benefit.","oneSentence":"Days 1,8,15, and 22 of the first 28-day cycle and then on Day 1 of subsequent 21-day cycles. The ant","technicalDetail":""},"commercial":null,"references":[],"biosimilars":[],"companyName":"Pfizer Inc.","competitors":[],"genericName":"anti-cd20-targeting-agent","indications":{"approved":[],"offLabel":[],"pipeline":[{"name":"Lymphoma","phase":"discontinued","trialId":"","patients":null,"diseaseId":"oncology","trialName":"","primaryEndpoint":"","expectedCompletion":""}]},"labelChanges":[],"relatedDrugs":[],"trialDetails":[{"nctId":"NCT01307267","phase":"discontinued","title":"A Study Of PF-05082566 As A Single Agent And In Combination With Rituximab","status":"discontinued","sponsor":"Pfizer","isPivotal":false,"enrollment":190,"indication":"Lymphoma, Non-Hodgkin","completionDate":"2019-02","primaryEndpoint":"A study of PF-05082566, a 4-1BB agonist monoclonal antibody (mAb), in patients with solid tumors or b-cell lymphomas, and in combination with rituximab in patients with CD20 positive Non-Hodgkin's Lym"},{"nctId":"NCT02663518","phase":"discontinued","title":"A Trial of PF-07901800 (TTI-621) for Patients With Hematologic Malignancies and Selected Solid Tumor","status":"discontinued","sponsor":"Pfizer","isPivotal":false,"enrollment":249,"indication":"Hematologic Malignancies","completionDate":"2022-11","primaryEndpoint":"Multicenter, open-label, phase 1a/1b trial of PF-07901800 (TTI-621) in subjects with relapsed or refractory hematologic malignancies and selected solid tumors."},{"nctId":"NCT03530683","phase":"discontinued","title":"A Clinical Trial to Learn About the Study Medicine Called Maplirpacept (PF-07901801), Alone and When","status":"discontinued","sponsor":"Pfizer","isPivotal":false,"enrollment":189,"indication":"Lymphoma","completionDate":"2024-07","primaryEndpoint":"The purpose of this clinical trial is to learn how the experimental medicine maplirpacept (PF-07901801) affects people with various types of blood cancers: * relapsed or refractory (R/R) lymphoma * mu"},{"nctId":"NCT05099471","phase":"discontinued","title":"Efficacy of Venetoclax in Combination With Rituximab in Waldenström's Macroglobulinemia","status":"discontinued","sponsor":"Christian Buske","isPivotal":false,"enrollment":80,"indication":"Waldenstrom Macroglobulinemia","completionDate":"2028-03","primaryEndpoint":"In Waldenström's macroglobulinemia (WM) chemotherapy induces only low CR/VGPR rates and response duration is limited."}],"genericFilers":[],"latestUpdates":[],"manufacturing":[],"administration":{"icon":"","route":"","frequency":"","formulation":""},"crossReferences":{"chemblId":"CHEMBL3956030"},"formularyStatus":[],"developmentCodes":[],"ownershipHistory":[],"therapeuticAreas":["Oncology"],"biosimilarFilings":[],"firstApprovalDate":"","companionDiagnostics":[],"firstApprovalCountry":null,"genericManufacturerList":[],"modality":"","enrichmentLevel":3,"visitCount":4,"trialStats":{"total":1,"withResults":0},"verificationStatus":"partial","dataCompleteness":{"mechanism":true,"indications":false,"safety":false,"trials":true,"score":2}}